Stock Analysis

Cyclo Therapeutics Full Year 2022 Earnings: Misses Expectations

Published
NasdaqCM:CYTH
Source: Shutterstock

Cyclo Therapeutics (NASDAQ:CYTH) Full Year 2022 Results

Key Financial Results

  • Revenue: US$1.38m (down 13% from FY 2021).
  • Net loss: US$15.5m (loss widened by 8.1% from FY 2021).
  • US$1.83 loss per share.
earnings-and-revenue-history
NasdaqCM:CYTH Earnings and Revenue History March 19th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cyclo Therapeutics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 42%. Earnings per share (EPS) also missed analyst estimates by 30%.

Looking ahead, revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 5.9% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 6 warning signs for Cyclo Therapeutics (of which 1 can't be ignored!) you should know about.

Valuation is complex, but we're helping make it simple.

Find out whether Cyclo Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis